Muscular Dystrophy Association Celebrates FDA Approval of argenx’s Vyvgart Hytrulo Injection for Treatment of Generalized Myasthenia Gravis
20 juin 2023 21h29 HE
|
Muscular Dystrophy Association
New York, June 20, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of subcutaneous (SC) Vyvgart Hytrulo (efgartigimod...
2 Day Training Course on the FDA (Food and Drug Administration) Drug Approval Process: June 14-15, 2023
15 juin 2023 04h13 HE
|
Research and Markets
Dublin, June 15, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
The FDA (Food and Drug Administration) Drug Approval Process Training Course: A Practical Insight into FDA Requirements
22 mai 2023 04h28 HE
|
Research and Markets
Dublin, May 22, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
25 avr. 2023 15h52 HE
|
Muscular Dystrophy Association
New York, April 25, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of Qalsody (tofersen), for the...
Muscular Dystrophy Association Celebrates FDA Approval of Skyclarys, First Ever Treatment for Friedreich’s Ataxia from Reata Pharmaceuticals
28 févr. 2023 20h18 HE
|
Muscular Dystrophy Association
New York, NY, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of Omaveloxolone (Skyclarys), the first ever...
Two Day FDA (Food and Drug Administration) Drug Approval Process Training Course: Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (October 10-11, 2022)
28 sept. 2022 08h13 HE
|
Research and Markets
Dublin, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The...
Outlook on the Acne Drugs Global Market to 2026 - Robust Acne Medications in Pipeline Presents Opportunities
14 janv. 2022 06h08 HE
|
Research and Markets
Dublin, Jan. 14, 2022 (GLOBE NEWSWIRE) -- The "Global Acne Drugs Market (2021-2026) by Acne Type, Therapeutic Class, Drug Type, Drug Formulation, Distribution Channel, and Geography, Competitive...
Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
29 sept. 2021 07h30 HE
|
Helsinn Healthcare S.A.
Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma - Health Canada Issues...
Global Orphan Drugs Market Report 2021-2026 Featuring Market Leaders - AbbVie, Eli Lilly, Johnson & Johnson, Merck & Co., Pfizer and Sanofi-Aventis
06 août 2021 04h53 HE
|
Research and Markets
Dublin, Aug. 06, 2021 (GLOBE NEWSWIRE) -- The "Global Markets for Orphan Drugs" report has been added to ResearchAndMarkets.com's offering. The Global Orphan Drug Market is Set to Grow to $191...
Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19
05 nov. 2020 08h04 HE
|
Arch Biopartners
TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient dosing in Turkey has begun in the Phase...